Metformin and the risk of endometrial cancer: A population-based cohort study

Gynecologic Oncology

Volumn 136, Issue 2, 2015, Pages 341-347

  Ko, Emily M ^a,b,c,e   Stürmer, Til ^a   Hong, Jin Liern ^a   Castillo, Wendy Camelo ^a,d   Bae Jump, Victoria ^b   Funk, Michele Jonsson ^a,b  

^a The University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cohort study; Endometrial cancer risk; Epidemiology; Metformin; Sulfonylurea

Indexed keywords

METFORMIN; ORAL CONTRACEPTIVE AGENT; SULFONYLUREA; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SURGERY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG WITHDRAWAL; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; FEMALE INFERTILITY; FOLLOW UP; HAZARD RATIO; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; UTERUS MYOMA; ENDOMETRIAL NEOPLASMS; INCIDENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; UNITED STATES;

ADULT; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; METFORMIN; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONYLUREA COMPOUNDS; UNITED STATES;

EID: 84923107157     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.12.001     Document Type: Article

References (48)

1. D.M. Nathan, J.B. Buse, M.B. Davidson, E. Ferrannini, R.R. Holman, R. Sherwin, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 2009 193 203
2. Administration USFaD, editor. FDA approved drug products: glucophage. U.S. Department of Health and Human Services; 2010.
3. Lexi-Comp. In: Lexi-Comp. 2010, editor. Metformin: drug Information. Lexi-Comp, Inc.; 2010
4. S. Bolen, L. Feldman, J. Vassy, L. Wilson, H.C. Yeh, S. Marinopoulos, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus Ann Intern Med 147 2007 386 399
5. W.C. Knowler, E. Barrett-Connor, S.E. Fowler, R.F. Hamman, J.M. Lachin, E.A. Walker, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
6. R.E. Ratner, C.A. Christophi, B.E. Metzger, D. Dabelea, P.H. Bennett, X. Pi-Sunyer, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions J Clin Endocrinol Metab 93 2008 4774 4779
7. S. Dronavalli, and D.A. Ehrmann Pharmacologic therapy of polycystic ovary syndrome Clin Obstet Gynecol 50 2007 244 254
8. S. Palomba, A. Falbo, F. Zullo, and F. Orio Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review Endocr Rev 30 2009 1 50
9. M.N. Pollak Investigating metformin for cancer prevention and treatment: the end of the beginning Cancer Discov 2 2012 778 790
10. M.S. Lee, C.C. Hsu, M.L. Wahlqvist, H.N. Tsai, Y.H. Chang, and Y.C. Huang Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals BMC Cancer 11 2011 20
11. C.J. Currie, J.R. Peters, A. Tynan, M. Evans, R.J. Heine, O.L. Bracco, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study Lancet 375 2010 481 489
12. G. Libby, L.A. Donnelly, P.T. Donnan, D.R. Alessi, A.D. Morris, and J.M. Evans New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes Diabetes Care 32 2009 1620 1625
13. D. Li, S.C. Yeung, M.M. Hassan, M. Konopleva, and J.L. Abbruzzese Antidiabetic therapies affect risk of pancreatic cancer Gastroenterology 137 2009 482 488
14. V. Donadon, M. Balbi, M.D. Mas, P. Casarin, and G. Zanette Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease Liver Int 30 2010 750 758
15. V. Donadon, M. Balbi, M. Ghersetti, S. Grazioli, A. Perciaccante, G. Della Valentina, et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease World J Gastroenterol 15 2009 2506 2511
16. M.M. Hassan, S.A. Curley, D. Li, A. Kaseb, M. Davila, E.K. Abdalla, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma Cancer 116 2010 1938 1946
17. M. Bodmer, C. Meier, S. Krahenbuhl, S.S. Jick, and C.R. Meier Long-term metformin use is associated with decreased risk of breast cancer Diabetes Care 33 2010 1304 1308
18. J.L. Bosco, S. Antonsen, H.T. Sorensen, L. Pedersen, and T.L. Lash Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark Cancer Epidemiol Biomarkers Prev 20 2011 11 101
19. J.L. Wright, and J.L. Stanford Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study Cancer Causes Control 20 2009 1617 1622
20. S.W. Lai, K.F. Liao, P.C. Chen, P.Y. Tsai, D.P. Hsieh, and C.C. Chen Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan Clin Lung Cancer 13 2012 143 148
21. S. Suissa, and L. Azoulay Metformin and the risk of cancer: time-related biases in observational studies Diabetes Care 35 2012 2665 2673
22. E.M. Ko, P. Walter, A. Jackson, L. Clark, J. Franasiak, C. Bolac, et al. Metformin is associated with improved survival in endometrial cancer Gynecol Oncol 132 2014 438 442
23. N.S. Nevadunsky, A. Van Arsdale, H.D. Strickler, A. Moadel, G. Kaur, M. Frimer, et al. Metformin use and endometrial cancer survival Gynecol Oncol 132 1 2014 236 240
24. N.S. Nevadunsky, A. Van Arsdale, H.D. Strickler, A. Moadel, G. Kaur, M. Frimer, et al. Metformin use and endometrial cancer survival Gynecol Oncol 132 2014 236 240
25. I.L. Romero, A. McCormick, K.A. McEwen, S. Park, T. Karrison, S.D. Yamada, et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity Obstet Gynecol 119 2012 61 67
26. T. Bjorge, A. Engeland, S. Tretli, and E. Weiderpass Body size in relation to cancer of the uterine corpus in 1 million Norwegian women Int J Cancer Journal international du cancer 120 2007 378 383
27. E. Friberg, C.S. Mantzoros, and A. Wolk Diabetes and risk of endometrial cancer: a population-based prospective cohort study Cancer Epidemiol Biomarkers Prev 16 2007 276 280
28. E. Friberg, N. Orsini, C.S. Mantzoros, and A. Wolk Diabetes mellitus and risk of endometrial cancer: a meta-analysis Diabetologia 50 2007 1365 1374
29. M.L. McCullough, A.V. Patel, R. Patel, C. Rodriguez, H.S. Feigelson, E.V. Bandera, et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype Cancer Epidemiol Biomarkers Prev 17 2008 73 79
30. V.W. Setiawan, H.P. Yang, M.C. Pike, S.E. McCann, H. Yu, Y.B. Xiang, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 31 2013 2607 2618
31. Z.H. Zhang, P.Y. Su, J.H. Hao, and Y.H. Sun The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies Int J Gynecol Cancer 23 2013 294 303
32. B. Thakkar, K.N. Aronis, M.T. Vamvini, K. Shields, and C.S. Mantzoros Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies Metabolism 62 2013 922 934
33. B. Kowall, W. Rathmann, and K. Kostev Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis Diabetes Care 2014 [pii: DC-140977, Epub ahead of print]
34. R. Ruiter, L.E. Visser, M.P. van Herk-Sukel, J.W. Coebergh, H.R. Haak, P.H. Geelhoed-Duijvestijn, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study Diabetes Care 35 2012 119 124
35. Truven health analytics: marketscan research databases 2013 Truven Health Analytics
36. W.A. Ray Evaluating medication effects outside of clinical trials: new-user designs Am J Epidemiol 158 2003 915 920
37. S. Setoguchi, D.H. Solomon, R.J. Glynn, E.F. Cook, R. Levin, and S. Schneeweiss Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data Cancer Causes Control 18 2007 561 569
38. H.J. Burstein, S. Temin, H. Anderson, T.A. Buchholz, N.E. Davidson, K.E. Gelmon, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update J Clin Oncol 32 2014 2255 2269
39. G.L. Anderson, M. Limacher, A.R. Assaf, T. Bassford, S.A. Beresford, H. Black, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712
40. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
41. W.M. Burke, J. Orr, M. Leitao, E. Salom, P. Gehrig, A.B. Olawaiye, et al. Endometrial cancer: a review and current management strategies: part I Gynecol Oncol Aug 134 2 2014 385 392
42. P.R. Rosenbaum, and D.B. Rubin The central role of the propensity score in observational studies for causal effects Biometrika 70 1983 41 55
43. T. Sturmer, K.J. Rothman, J. Avorn, and R.J. Glynn Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution - a simulation study Am J Epidemiol 172 2010 843 854
44. C. Becker, S.S. Jick, C.R. Meier, and M. Bodmer Metformin and the risk of endometrial cancer: a case-control analysis Gynecol Oncol 129 2013 565 569
45. J. Luo, S. Beresford, C. Chen, R. Chlebowski, L. Garcia, L. Kuller, et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer Br J Cancer 111 2014 1432 1439
46. R.J. Stevens, R. Ali, C.R. Bankhead, M.A. Bethel, B.J. Cairns, R.P. Camisasca, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials Diabetologia 55 2012 2593 2603
47. A.E. Buchs, and B.G. Silverman Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study Metab Clin Exp 60 2011 1379 1385
48. C.J. Currie, C.D. Poole, and E.A. Gale The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia 52 2009 1766 1777